# Beam Therapeutics Inc.: overview

BEAM · Nasdaq · CIK 1745999 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/beam.md) · [Financials](/companies/beam/financials.md) · [Filings](/companies/beam/filings.md) · [Insiders](/companies/beam/insiders.md)

Latest reported revenue: [$490.0k](/filings/0001193125-26-331541.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-331541).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [14.3](/filings/0001193125-25-263542.md) | [30.1 d](/filings/0001193125-26-065194.md) | [7.5](/filings/0001193125-26-210338.md) | [8.5](/filings/0001193125-26-331541.md) | [9.7](/filings/0001193125-25-263542.md) | [114 d](/filings/0001193125-26-065194.md) | [31.7](/filings/0001193125-26-210338.md) | [0.5](/filings/0001193125-26-331541.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(746.4%)](/filings/0001193125-25-263542.md) | [(332.7%) d](/filings/0001193125-26-065194.md) | [(1596.9%)](/filings/0001193125-26-210338.md) | [(1419.2%)](/filings/0001193125-26-331541.md) | [(1307.6%)](/filings/0001193125-25-263542.md) | [(15.3%) d](/filings/0001193125-26-065194.md) | [(337.8%)](/filings/0001193125-26-210338.md) | [(25827.1%)](/filings/0001193125-26-331541.md) |
| Net margin | % | [(677.5%)](/filings/0001193125-25-263542.md) | [(300.5%) d](/filings/0001193125-26-065194.md) | [(1450.2%)](/filings/0001193125-26-331541.md) | [(1206.4%)](/filings/0001193125-26-331541.md) | [(1162.4%)](/filings/0001193125-25-263542.md) | [214.1% d](/filings/0001193125-26-065194.md) | [(297.2%)](/filings/0001193125-26-331541.md) | [(25036.3%)](/filings/0001193125-26-331541.md) |
| Diluted EPS | $ per share | [(1.17)](/filings/0001193125-25-263542.md) | not reported | [(1.23)](/filings/0001193125-26-210338.md) | [(1.00)](/filings/0001193125-26-331541.md) | [(1.10)](/filings/0001193125-25-263542.md) | not reported | [(0.91)](/filings/0001193125-26-210338.md) | [(1.18)](/filings/0001193125-26-331541.md) |
| Free cash flow | $m | [(89.7) d](/filings/0001193125-25-263542.md) | [(79.3) d](/filings/0001193125-26-065194.md) | [(107)](/filings/0001193125-26-210338.md) | [(79.6) d](/filings/0001193125-26-331541.md) | [(86.5) d](/filings/0001193125-25-263542.md) | [(87.0) d](/filings/0001193125-26-065194.md) | [(131)](/filings/0001193125-26-210338.md) | [(68.5) d](/filings/0001193125-26-331541.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [51.8](/filings/0000950170-24-020622.md) | [60.9](/filings/0000950170-25-026076.md) | [378](/filings/0001193125-26-065194.md) | [63.5](/filings/0001193125-26-065194.md) | [140](/filings/0001193125-26-065194.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(757.0%)](/filings/0000950170-24-020622.md) | [(555.6%)](/filings/0000950170-25-026076.md) | [(46.7%)](/filings/0001193125-26-065194.md) | [(654.3%)](/filings/0001193125-26-065194.md) | [(274.6%)](/filings/0001193125-26-065194.md) |
| Net margin | % | [(714.9%)](/filings/0000950170-24-020622.md) | [(474.5%)](/filings/0000950170-25-026076.md) | [(35.1%)](/filings/0001193125-26-065194.md) | [(593.1%)](/filings/0001193125-26-065194.md) | [(57.2%)](/filings/0001193125-26-065194.md) |
| Diluted EPS | $ per share | [(5.77)](/filings/0000950170-24-020622.md) | [(4.13)](/filings/0000950170-25-026076.md) | [(1.72)](/filings/0001193125-26-065194.md) | [(4.58)](/filings/0001193125-26-065194.md) | [(0.81)](/filings/0001193125-26-065194.md) |
| Free cash flow | $m | [(113)](/filings/0000950170-24-020622.md) | [(26.4)](/filings/0000950170-25-026076.md) | [(183)](/filings/0001193125-26-065194.md) | [(356)](/filings/0001193125-26-065194.md) | [(360)](/filings/0001193125-26-065194.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/beam/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $432.7m | 12,609,002 |  | Added +156,803 |
| [FARALLON CAPITAL MANAGEMENT, L.L.C.](/funds/909661.md) | 2026-06-30 | $351.3m | 10,236,396 |  | Added +101,700 |
| [ARK Investment Management LLC](/funds/1697748.md) | 2026-06-30 | $351.3m | 10,234,862 |  | Reduced −1,898,571 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $308.8m | 8,997,542 |  | Added +509,973 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $200.0m | 5,827,122 |  | Added +127,857 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $168.9m | 4,921,259 |  | Added +350,462 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $157.9m | 4,599,437 |  | Added +222,063 |
| [ARCH Venture Management, LLC](/funds/1274403.md) | 2026-06-30 | $155.8m | 4,540,132 |  | Unchanged |
| [Sumitomo Mitsui Trust Group, Inc.](/funds/1475365.md) | 2026-06-30 | $118.6m | 3,455,043 |  | Reduced −370,542 |
| [Amova Asset Management Americas, Inc.](/funds/1480751.md) | 2026-06-30 | $118.5m | 3,455,043 |  | Reduced −370,542 |

## Recent filings

[All 506 filings](/companies/beam/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-04 | 11:13 ET | [10-Q](/filings/0001193125-26-331541.md) | Quarterly report, period 2026-06-30 | 0001193125-26-331541 |
| 2026-08-04 | 11:09 ET | [8-K](/filings/0001193125-26-331522.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-331522 |
| 2026-06-08 | 20:05 ET | [8-K](/filings/0001193125-26-261693.md) | 5.07 Shareholder vote results | 0001193125-26-261693 |
| 2026-05-07 | 11:22 ET | [10-Q](/filings/0001193125-26-210338.md) | Quarterly report, period 2026-03-31 | 0001193125-26-210338 |
| 2026-05-07 | 11:06 ET | [8-K](/filings/0001193125-26-210299.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-210299 |
| 2026-04-17 | 20:05 ET | [DEF 14A](/filings/0001193125-26-161512.md) | Proxy statement, period 2026-06-03 | 0001193125-26-161512 |
| 2026-03-05 | 21:05 ET | [8-K](/filings/0001193125-26-093914.md) | 1.02 Termination of a material agreement | 0001193125-26-093914 |
| 2026-02-24 | 12:10 ET | [10-K](/filings/0001193125-26-065194.md) | Annual report, period 2025-12-31 | 0001193125-26-065194 |
| 2026-02-24 | 12:05 ET | [8-K](/filings/0001193125-26-065191.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-065191 |
| 2026-02-12 | 21:05 ET | [8-K](/filings/0001193125-26-048684.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-048684 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-065194.md), filed Feb 24, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/cf48cede-bf7b-40dc-8798-9f0808ca27fb)

## About the filer

- CIK: 1745999
- Tickers: BEAM
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.